2 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18576990 | Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease | ROZOF, TIMOTHY R | 1625 | Non-Final OA | Jan 05, 2024 |
| 18576973 | OXAFURAMINE, (1R)-N-ETHYL-1-[(2R)-OXOLAN-2-YL]-2-PHENYLETHANAMINE, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR TREATING ALZHEIMER'S DISEASE (AD), VASCULAR DEMENTIA, DEMENTIA WITH LEWY BODIES (DLB), MIXED DEMENTIA, FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AND PARKINSON'S DISEASE (PD) | BAUER, NICOLA MARIA | 1621 | Non-Final OA | Jan 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial